Compare AbbVie Inc (ABBV) vs Wahed FTSE USA Shariah ETF (HLAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Wahed FTSE USA Shariah ETF — how do they compare? AbbVie Inc trades at $248.52 (market cap $441.94B), while Wahed FTSE USA Shariah ETF trades at $72.95. The key difference: AbbVie Inc pays a 2.77% dividend while Wahed FTSE USA Shariah ETF pays none, and Wahed FTSE USA Shariah ETF is trading nearer its 52-week high, AbbVie Inc nearer its low. Which is the better fit depends on your goals.
| ABBV | HLAL | |
|---|---|---|
Market Cap | $441.94B | — |
Sector | Health | Sector/Thematic |
52-Week High | $263.58 | $73.60 |
52-Week Low | $197.38 | $55.52 |
Enterprise Value | $506.19B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.9, up 0.8% on the day, with strong analyst support (29 Buy, 1 Sell) and a $278.69 consensus price target. Recent quarterly earnings have consistently beaten estimates, driven by robust immunology drug sales. The stock shows a bullish technical trend, supported by moving averages, and the company maintains solid cash flow and dividend payments.
Outlook is positive with revenue growth and pipeline advancements, though high P/E and debt levels pose risks. The stock offers a compelling buy case for growth and income investors, balanced by execution and patent expiry challenges ahead.
HLAL trades at $73.11 with a slight 0.19% daily gain, showing bullish technical momentum with strong moving average support. The stock lacks key valuation metrics (P/E, P/S, P/B) in current data, and a small dividend of $0.02 is scheduled for June 2026. Technical indicators show mixed signals with RSI suggesting potential overbought conditions near-term.
The outlook remains cautiously optimistic given bullish technical trends, but limited fundamental data and high RSI levels near 95 warrant monitoring. Key risks include reliance on technical momentum without clear valuation anchors, while institutional sentiment appears constructive based on moving average alignment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Wahed FTSE USA Shariah ETF
HLAL is an ETF that invests in Shariah-compliant US companies. It follows a rigorous screening process to exclude businesses involved in non-compliant activities like interest-based finance, alcohol, and gambling.
Read more on HLAL →
